Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-escalation study of Zevalin before BEAM and autologous stem cell transplantation in relapsed or refractory aggressive non-Hodgkin lymphoma
2004-003801-26Phase 2Completed
- Sponsor
- Institut für anwendungsorientierte Forschung und klinische Studien
- Start
- Nov 2004
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in non-Hodgkin lymphoma (NHL) and aggressive lymphoma, sponsored by Institut für anwendungsorientierte Forschung und klinische Studien. Primary endpoints: Maximum usable dose of yttrium-90 Zevalin before BEAM and autologous stem cell transplantation and Frequency of grade III and IV pulmonary toxicity. Started Nov 2004; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
non-Hodgkin lymphoma (NHL)aggressive lymphoma
Beyond the preview
Go deeper on 2004-003801-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003801-26.